Pharmaceutical manufacturing equipment must be properly cleaned to ensure the removal of product residue, cleaning chemical residue, and microbes prior to manufacturing. Because cleaning methods are developed and validated to prevent the risk of producing contaminated products by confirming that the cleaning process is sufficient, it’s important to establish method limits and select the proper cleaning techniques and detection methods.
In today’s ever-evolving business world, the need to do more with less has never been greater. And the need to do it better, faster, and safer is equally essential. Saving time, money, and natural resources are paramount priorities across all industries. This is especially true in health care and pharmaceuticals. With an increased focus on minimizing errors and costs while maximizing efficiencies and value, companies are throwing paper-based processes into the trash. Advanced technologies such as barcoding are taking their place, helping the health care and pharmaceutical industries save time, money, and environmental resources.
Pharmaceutical companies face constantly increasing challenges in bringing new drugs to market, and even when they make it to market, strong threats can prevail. The rising costs of development, increased competition, and shorter periods of exclusivity have placed even greater emphasis on product life cycle management (PLM) as a means of maximizing return on investment. Today’s best practitioners apply PLM principles at an early stage in a product’s development and consider a broad range of technical and commercial options to create integrated PLM strategies. By grouping the issues under five rules with selected examples, this article examines the harsh realities of today’s PLM environment and the clear trends in industry practice.
FROM OUR NEWSLETTER
Stay in the loop with our free, semi-monthly eNewsletter. Sign up today!
Chitosan has been widely studied for pharmaceutical applications, but its usefulness has been restricted because of its limited solubility. Now researchers in India are studying trimethyl chitosan, a more soluble form, for pharmaceutical uses, including nanoformulations.
Iron oxide nanoparticles conjugated with chlorotoxin—a scorpion venom compound—slowed brain tumor growth by 98%, researchers report. The combination more than doubled the effect of chlorotoxin alone, the researchers found. "The aim of most experimental therapy with nanoparticles right now is to kill cancer cells," said Miqin Zhang, PhD.
Delivery of a tumor-suppressor gene to tumor cells using liposomes is showing promise in early human clinical trials, according to researchers. The therapy delivers a functioning p53 gene to tumor cells, which prompts the cells either to repair themselves or undergo programmed cell death, said Esther H. Chang, PhD.
